Search clinical trials for: MEDI9447 (oleclumab)

Total 41 results

AstraZeneca

Completed

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Advanced Solid Malignancies

Japan
University Health Network, Toronto

Recruiting

Durvalumab and Oleclumab in Resectable PDAC (DORA)

Pancreatic Ductal Adenocarcinoma

Canada
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
Dana-Farber Cancer Institute
AstraZeneca

Completed

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Muscle Invasive Bladder Cancer

United States
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
MedImmune LLC

Active, not recruiting

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Taiwan
Jules Bordet Institute
AstraZeneca

Active, not recruiting

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY)

Triple Negative Breast Cancer

France, Belgium
Assistance Publique Hopitaux De Marseille

Active, not recruiting

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

Non-small Cell Lung Cancer

France
MedImmune LLC

Terminated

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Metastatic Microsatellite-stable Colorectal Cancer

United States, Spain, France, Australia, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
AstraZeneca

Recruiting

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

Triple Negative Breast Neoplasms

United States, Korea, Republic of, Canada, Taiwan, United Kingdom, Poland
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
MedImmune LLC

Completed

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Solid Tumors

United States, Korea, Republic of, Australia
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
MedImmune LLC

Completed

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Diffuse Large B-cell Lymphoma

United States, France, Korea, Republic of
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
AstraZeneca
Parexel

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

Non-small Cell Lung Cancer

Hungary, United States, Italy, Belgium, Spain, France, Korea, Republic of, Taiwan, Turkey, Ireland, Portugal, Canada
MedImmune LLC

Completed

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Carcinoma | Metastatic Pancreatic Adenocarcinoma

United States, Spain, Australia, Norway
AstraZeneca

Completed

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)

United States
University Health Network, Toronto
AstraZeneca

Withdrawn

A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)

Renal Cell Carcinoma | Non Small Cell Lung Cancer

Canada
University Health Network, Toronto
AstraZeneca

Withdrawn

A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)

Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Canada
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
MedImmune LLC

Completed

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Small Cell Lung Cancer (SCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC) | Non Small Cell Lung Cancer Squamous (NSCLC-Sq)

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Withdrawn

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Oropharynx Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
MedImmune LLC

Completed

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Head and Neck Cancer | Human Papilloma Virus

United States
MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Access to Advanced...

Not yet recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate

Hiv
National Institute of Allergy and Infectious Diseases...

Recruiting

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Chronic HIV Infection

United States
International AIDS Vaccine Initiative
3M; Polymun Scientific GmbH; Access to Advanced Health Institute (AAHI)

Enrolling by invitation

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Hiv

Netherlands
National Institute of Allergy and Infectious Diseases...
Department of Health and Human Services; HIV Vaccine Trials Network; Inovio Pharmaceuticals and other collaborators

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

HIV Infections

United States, South Africa
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

HIV-1-infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Stage IV Anal Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Neoplasm | Stage IV Penile Cancer AJCC v8 | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Stage IV Cervical Cancer AJCC v8 | Stage IVA Cervical Cancer AJCC v8 | Stage IVB Cervical Cancer AJCC v8 | Stage... and other conditions

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

Hiv

United States
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
National Institute of Allergy and Infectious Diseases...
Fred Hutchinson Cancer Center; International AIDS Vaccine Initiative; HIV Vaccine... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Duke University; National Institutes of Health (NIH); Department of Health and... and other collaborators

Not yet recruiting

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

HIV

United States, South Africa

Search clinical trials for: MEDI9447 (oleclumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations